Travere Therapeutics
Travere Therapeutics Logo
About Travere Therapeutics
Travere Therapeutics, Inc. is a biopharmaceutical company focused on identifying, developing, and delivering therapies for people living with rare kidney and metabolic diseases. The company’s products include FILSPARI (sparsentan), an oral medication for IgA Nephropathy, and Thiola and Thiola EC (tiopronin tablets) for the treatment of cystinuria, a rare genetic disorder. Travere Therapeutics also has clinical-stage programs such as Sparsentan for focal segmental glomerulosclerosis and Pegtibatinase (TVT-058) for classical homocystinuria. The company collaborates with partners to advance pre-clinical activities and is dedicated to improving the lives of patients with rare diseases worldwide.
Address
3611 Valley Centre Drive, Suite 300
San Diego, 92130
United States
Year founded
2008
Number of employees
300-400
Sector
Health Care
Industry Group
Pharmaceuticals, Biotechnology & Life Sciences
Industry
Biotechnology
Report inaccurate data
Request an update to help us keep the brand up-to-date.
